Detailed definition
Osteopenia, also called low bone mass, is defined by a DEXA T-score between -1.0 and -2.5 at the hip or lumbar spine. It is not a disease per se but a risk state for future osteoporosis and fragility fracture. Approximately half of postmenopausal US women have osteopenia. Management depends on absolute fracture risk (using the FRAX 10-year calculator), not just BMD. Foundational measures: calcium 1000–1200 mg/day from food preferentially, vitamin D 800–1000 IU/day if deficient, weight-bearing and resistance exercise, smoking cessation, alcohol moderation, and fall-prevention. Pharmacologic therapy is generally reserved for women with FRAX-predicted 10-year hip fracture risk ≥3% or major osteoporotic fracture risk ≥20%, OR for women with osteopenia plus a prior fragility fracture. HRT prevents bone loss effectively when started in the timing window.
Why it matters in menopause
A DEXA showing osteopenia at age 52 is not a sentence to medication — it is an opportunity to address modifiable risk and to weigh whether HRT (already considered for symptoms) provides the additional bone benefit needed to avoid future osteoporosis. Many women on HRT for vasomotor symptoms see osteopenia plateau or improve over years.
Related terms
Sources
External references: Wikipedia.